Aging
Conditions
Interventions
Treatment group:Bazi Bushen Capsules: 2 capsules per dose, administered orally three times daily (2 capsules per administration, TID).
Control Group:Placebo
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Age = 50 years. (2) Evidence of reduced intrinsic capacity, or a score = 10 on the Traditional Chinese Medicine (TCM) Aging Evaluation Scale. (3) Provision of written informed consent.
Exclusion criteria
Exclusion criteria: (1) Severe disease or unstable clinical status attributable to age-related changes of major organs. (2) Severe hepatic or renal insufficiency, malignant neoplasm, hematologic disorder, or other serious diseases of the cardiovascular, respiratory, or neurological systems (e.g., moderate-to-severe Parkinson's disease or Alzheimer's disease). (3) Severe psychiatric disorders or significant cognitive impairment. (4) Presence of physical disabilities that would impede participation. (5) Meeting diagnostic criteria for, or habitually exhibiting, Traditional Chinese Medicine patterns such as liver-yang hyperactivity, excess-heat (shi-heat), damp-heat, or yin-deficiency with internal heat. (6) History of alcohol abuse or substance dependence within 1 year prior to screening. (7) Participation in another investigational drug trial within 1 month prior to screening. (8) Known or suspected hypersensitivity/allergy to the investigational product or its excipients, or a history of atopy. (9) Any other condition that, in the investigator's judgment, would render the subject unsuitable for participation due to potential protocol noncompliance or safety concerns.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biological age; | — |
Secondary
| Measure | Time frame |
|---|---|
| Score on the Traditional Chinese Medicine (TCM) Aging Evaluation Scale.;Metrics of multimodal biological age (i.e., indicators reflecting biological age derived from multiple modalities).;Peripheral blood aging biomarkers;Comprehensive geriatric assessment score;Adverse reaction/event occurrence rate; | — |
Countries
China
Contacts
Public ContactPing Zhu
Chinese PLA General Hospital
Outcome results
None listed